United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 1 mg in 1 ml - - in the treatment of parkinsonism. rigidity and tremor relieved by the apparently selective depressant action. - in the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. - to relieve hypertonicity of the uterine muscle. - to relax the spasm of biliary and uretered colic and bronchial spasm. - to diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. - to control the crying and laughing episodes in patients with brain lesions. - in cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns, stupor and neurological signs. - in the management of peptic ulcer. - in anesthesia to control excessive salivation and bronchial secretions. - to control rhinorrhea of acute rhinitis or hay fever. - as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 0.4 mg in 1 ml - 1. in the treatment of parkinsonism. rigidity and tremor relieved by the apparently selective depressant action. 2. in the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. 3. to relieve hypertonicity of the uterine muscle. 4. to relax the spasm of biliary and uretered colic and bronchial spasm. 5. to diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. 6. to control the crying and laughing episodes in patients with brain lesions. 7. in cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns, stupor and neurological signs. 8. in the management of peptic ulcer. 9. in anesthesia to control excessive salivation and bronchial secretions. 10. to control rhinorrhea of acute rhinitis or hay fever. 11. as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain

United States - English - NLM (National Library of Medicine)

cardinal health - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 0.4 mg in 1 ml

United States - English - NLM (National Library of Medicine)

sparhawk laboratories, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 15 mg in 1 ml - for use as an antidote in the treatment of organophosphate insecticide poisoning of cattle, horses and sheep.

United States - English - NLM (National Library of Medicine)

ocusoft, inc. - homatropine hydrobromide (unii: bew7469qz0) (homatropine - unii:8qs6wcl55z) - a moderately long-acting mydriatic and cycloplegic for cycloplegic refraction and in the treatment of inflammatory conditions of the uveal tract. for pre and postoperative states when mydriasis is required. use as an optical aid in some cases of axial lens opacities. contraindicated in persons with primary glaucoma or a tendency toward glaucoma, e.g. narrow anterior chamber angle, and in those persons showing hypersensitivity to any component of this preparation.   homatropine should not be used during the first three months of life due to a possible association between the cycloplegia produced and the development of amblyopia. patient should be advised not to drive or engage in other hazardous activities while pupils are dilated. patient may experience sensitivity to light and should protect eyes in bright illumination during dilation. parents should be warned not to get this preparation in their child’s mouth and to wash their own hands and the child's hands following administration. do not touch dropper

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - indications as at 23 october 2001: preanaesthetic medication to reduce salivary secretions and bronchial secretions. to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia. management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability. concurrent administration with anticholinesterase agents (eg. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation. for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - atropine sulfate - solution for injection in a pre-filled syringe - atropine sulfate 0.1 mg/ml - drugs for functional gastrointestinal disorders

United States - English - NLM (National Library of Medicine)

avpak - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - for mydriasis and/or cycloplegia. for cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract. this product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma. this product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. this product should not be used in those persons showing hypersensitivity to any component of this preparation.

United States - English - NLM (National Library of Medicine)

sebela pharmaceuticals inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), difenoxin hydrochloride (unii: vqz63k01iw) (difenoxin - unii:3zz5bj9f2q) - atropine sulfate 0.025 mg - motofen® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. motofen® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic e. coli, salmonella species, shigella ) and pseudomembranous colitis associated with broad spectrum antibiotics. antiperistaltic agents should not be used in the conditions because they may prolong and/or worsen diarrhea. motofen® is contraindicated in children under 2 years of age because of the decreased margin of safety of drugs in this class in younger age groups. motofen® is contraindicated in patients with a known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced. motofen® tablets are a schedule iv controlled substance. addiction to (dependence on) difenoxin hydrochloride is theoretically possible at high dosage. therefore, the recommended dosage should not be e